The IL‐6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B‐cell lymphoma

Interleukin‐6 (IL‐6) is a growth factor for normal B cells and plasma cell‐derived malignancies. Here, we show that the IL‐6 signaling pathway is also active in a subset of diffuse large B‐cell lymphoma (DLBCL) patients with particularly poor prognosis. Primary DLBCL cells and DLBCL cell lines expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashwah, Hind, Bertram, Katrin, Stirm, Kristin, Stelling, Anna, Wu, Cheuk‐Ting, Kasser, Sabrina, Manz, Markus G, Theocharides, Alexandre P, Tzankov, Alexandar, Müller, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783642/
https://www.ncbi.nlm.nih.gov/pubmed/31515941
http://dx.doi.org/10.15252/emmm.201910576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783642/
https://www.ncbi.nlm.nih.gov/pubmed/31515941
http://dx.doi.org/10.15252/emmm.201910576

Ejemplares similares